Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells

Journal of Experimental Medicine

Volumn 195, Issue 1, 2002, Pages 125-133

  Dhodapkar, Kavita M ^a   Krasovsky, Joseph ^a   Williamson, Barbara ^c   Dhodapkar, Madhav V ^a,b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

Cancer testis antigens; Fc receptors; Immunotherapy; Myeloma; Tumor immunity

Indexed keywords

CANCER ANTIBODY; CELL ANTIGEN; FC RECEPTOR; MONOCLONAL ANTIBODY; SYNDECAN ANTIBODY; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELL MATURATION; CELL STIMULATION; DENDRITIC CELL; HUMAN; HUMAN CELL; KILLER CELL; MYELOMA; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; APOPTOSIS; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; KILLER CELLS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PROTEINS; PROTEOGLYCANS; RECEPTORS, IGG; SYNDECANS; T-LYMPHOCYTES; TESTICULAR NEOPLASMS;

EID: 0037033448     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20011097     Document Type: Article

References (33)

1. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes
2. Cross-presentation, dendritic cells, tolerance and immunity
3. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells
4. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses
5. + killer T cells
6. + T cells for efficient tumor cell lysis
7. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells
8. + T lymphocyte responses
9. Immunity against cancer: Lessons learned from melanoma
10. Monoclonal antibody therapies-a 'constant' threat to cancer
11. Fc receptors are required in passive and active immunity to melanoma
12. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
13. Expression of cancer-testis antigens in lung cancer: Definition of bromo-domain testis-specific gene (BRDT) as a new CT gene, CT9
14. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1
15. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
16. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions
17. A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use
18. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization
19. Class 1-restricted presentation of exogenous antigen acquired by Fcγ receptor-mediated endocytosis is regulated in dendritic cells
20. Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
21. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells
22. Fc receptors for IgG and antigen presentation on MHC class I and class II molecules
23. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α
24. Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor Fcγ RI (CD64) expressed on human blood dendritic cells
25. Immune complex and Fc receptor-mediated augmentation of antigen presentation for in vivo Th cell responses
26. Transport of macrophage Fc receptors and Fc receptor-bound ligands to lysosomes
27. Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies
28. Exogenous antigen targeted to FcγRI on myeloid cells is presented in association with MHC class I
29. Modulation of proteasomal activity, required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3
30. Type II and III receptors for immunoglobulin G (IgG) control the presentation of different T cell epitopes from single IgG-complexed antigens
31. Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor
32. + cells in eliminating an established tumor
33. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: Induction of inflammatory responses at tumor sites